Immunosuppresant; Sphingosine-1-phosphate receptor agonist. Limits 'cytokine storm'. Wan-Jin Chen, Phase II clinical trial "Efficacy of Fingolimod in the Treatment of New Coronavirus Pneumonia (COVID-19)" April 2020, https://clinicaltrials.gov/ct2/show/NCT04280588.
Biochemicals & reagents
1) Brinkmann et al. (2002), The immune modulator FTY720 targets spingosine-1-phosphate receptors; J. Biol. Chem., 277 21453 2) Wolf et al. (2009), The sphingosine 1-phosphate receptor agonist FTY720 potently inhibits regulatory T cell proliferation in vitro and in vivo; J. Immunol., 183 3751 3) Awojoodu et al. (2013), Sphingosine 1-phosphate receptor 3 regulates recruitment of anti-inflammatory monocytes to microvessels during implant arteriogenesis; Proc. Natl. Acad. Sci. USA, 110 13785 4) Chiba (2005), FTY720, a new class of immunomodulator, inhibits lymphocyte egress from secondary lymphoid tissues and thymus by agonistic activity at sphingosine 1-phosphate receptors; Pharmacol. Ther., 108 308
Fingolimod (FTY-720) is an analog of sphingosine which, when taken up into cells, is phosphorylated and acts as an agonist at sphingosine-1-phosphate receptors (S1P1/3) (1). This compound potently inhibits regulatory T cell proliferation in vitro and in vivo (2), enhances microvascular remodeling via expansion of arterioles and capillary networks (3). It is also a potent immunomodulator (4).